Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Treatment    save search

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
LEGN | News | $52.71 -2.1% -2.14% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 2.98% H: 0.0% C: 0.0%

carvykti treatment biotech study
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Published: 2023-01-27 (Crawled : 21:00) - biospace.com/
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M twitter stocktwits trandingview |
Health Technology
| | O: -0.5% H: 0.0% C: 0.0%

carvykti treatment study
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | News | $72.45 -0.74% 0.0% 5.4M twitter stocktwits trandingview |
Health Technology
| | O: -0.27% H: 0.0% C: 0.0%
AMGN | News | $253.68 -0.47% -0.47% 2.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 0.0% C: 0.0%

treatment for chmp psoriasis positive
EastGroup Properties Announces the Income Tax Treatment of its 2022 Distributions
Published: 2023-01-27 (Crawled : 01:00) - prnewswire.com
EGP | News | $168.77 1.07% 0.0% 280K twitter stocktwits trandingview |
Finance
| | O: 0.89% H: 0.0% C: 0.0%

treatment
NexPoint Real Estate Finance, Inc. Announces 2022 Dividend Income Tax Treatment
Published: 2023-01-26 (Crawled : 00:00) - prnewswire.com
NREF | $19.22 1.16% 0.0% 35K twitter stocktwits trandingview |
Finance
| | O: -1.76% H: 0.0% C: 0.0%

treatment dividend
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Published: 2023-01-26 (Crawled : 00:00) - globenewswire.com
BIIB A | $290.0 -0.66% -0.66% 890K twitter stocktwits trandingview |
Health Technology
| | O: 0.46% H: 0.0% C: 0.0%

treatment lecanemab disease for application alzheimer’s authorization
Prologis Announces Tax Treatment of 2022 Dividends
Published: 2023-01-26 (Crawled : 22:00) - prnewswire.com
PLD A | $129.84 1.39% 0.0% 2.8M twitter stocktwits trandingview |
Finance
| Email alert Add to watchlist
DRE | $48.2 0.0% twitter stocktwits trandingview |
Finance
| Email alert Add to watchlist

treatment dividends
Prologis Announces Tax Treatment of Duke Realty Corporation's 2022 Dividends
Published: 2023-01-26 (Crawled : 22:00) - prnewswire.com
PLD A | $129.84 1.39% 0.0% 2.8M twitter stocktwits trandingview |
Finance
| Email alert Add to watchlist
DRE | $48.2 0.0% twitter stocktwits trandingview |
Finance
| Email alert Add to watchlist

treatment dividends
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
COYA | $4.58 -0.65% -0.66% 13K twitter stocktwits trandingview |
| | O: -3.16% H: 3.69% C: 0.22%

treatment disease preclinical animal alzheimer’s potential
Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
PEAR S | $1.085 -9.58% -10.6% 370K twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 2.68% H: 6.96% C: 4.35%

treatment for health program therapeutics
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
SLNO A | $2.83 9.27% 8.48% 110K twitter stocktwits trandingview |
Health Technology
| | O: -1.24% H: 32.22% C: 8.37%

treatment for trial therapeutics results publication
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
Published: 2023-01-26 (Crawled : 14:00) - biospace.com/
RDHL | $0.214 16.24% 13.97% 100M twitter stocktwits trandingview |
Health Technology
| | O: 8.77% H: 4.3% C: -1.02%

rhb-204 treatment patent disease for
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
Published: 2023-01-26 (Crawled : 14:00) - globenewswire.com
TGTX | $14.63 3.39% 3.28% 4M twitter stocktwits trandingview |
Health Technology
| | O: 3.13% H: 0.34% C: -2.28%

treatment for commercial therapeutics sclerosis
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Published: 2023-01-26 (Crawled : 13:00) - biospace.com/
SYRS | $4.5 1.81% 1.78% 90K twitter stocktwits trandingview |
Health Technology
| | O: 5.79% H: 2.41% C: -3.28%

treatment fda designation for
Worldwide Orthopedic Oncology Treatment Industry to 2030 - Dominating Segment is Reconstructive Surgery
Published: 2023-01-26 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $97.85 0 twitter stocktwits trandingview |
Health Technology
| | O: -0.49% H: 0.0% C: 0.0%
NVSEF | News 4 d | $90.0 0 twitter stocktwits trandingview |
Health Technology
| | O: -1.1% H: 0.0% C: 0.0%
ZBH | News | $125.88 0.3% 0.0% 1.4M twitter stocktwits trandingview |
Health Technology
| | O: 1.12% H: 0.0% C: 0.0%
SYK | News | $254.17 0.7% 0.0% 1M twitter stocktwits trandingview |
Health Technology
| | O: 0.78% H: 0.0% C: 0.0%
NVS | News 4 d | $89.49 -0.39% 0.01% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: -1.25% H: 0.0% C: 0.0%
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M twitter stocktwits trandingview |
Health Technology
| | O: 1.29% H: 0.0% C: 0.0%
SNY | News | $48.49 -0.66% -0.66% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.89% H: 0.0% C: 0.0%

treatment
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Published: 2023-01-25 (Crawled : 23:00) - globenewswire.com
SNYNF | News | $97.85 0 twitter stocktwits trandingview |
Health Technology
| | O: -0.49% H: 0.0% C: 0.0%
SNY | News | $48.49 -0.66% -0.66% 1.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.89% H: 0.0% C: 0.0%

treatment for potential
Macerich Announces Tax Treatment Of 2022 Dividends
Published: 2023-01-25 (Crawled : 22:00) - prnewswire.com
MAC | News A | $13.67 3.01% -0.51% 1.6M twitter stocktwits trandingview |
Finance
| | O: 4.94% H: 0.0% C: 0.0%

treatment dividends
UMH PROPERTIES, INC. ANNOUNCES TAX TREATMENT FOR 2022 DISTRIBUTIONS
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
UMH 4 | $17.21 0.82% 0.0% 180K twitter stocktwits trandingview |
Finance
| | O: 0.83% H: 0.94% C: 0.77%

treatment for
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
Published: 2023-01-25 (Crawled : 21:00) - globenewswire.com
ARDS | $0.7016 -12.3% -14.03% 3.1M twitter stocktwits trandingview |
Health Technology
| | O: -5.53% H: 2.17% C: -13.04%

ar-301 treatment for trial results
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
CMND | $3.88 2.38% 2.32% 79K twitter stocktwits trandingview |
n/a
| | O: 11.62% H: 0.0% C: 0.0%
JNJ | News 3 d | $168.23 -0.39% -0.04% 6M twitter stocktwits trandingview |
Health Technology
| | O: -0.04% H: 0.0% C: 0.0%

treatment obesity biotech
Gainers vs Losers
66% 34%

Top 10 Gainers

Your saved searches
Save your searches and get alerts when important news are released.